Skip to content

    Colorectal Cancer Health Center

    Font Size

    Colon Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage III Colon Cancer Treatment


    Chemotherapy regimens after 2000


    Capecitabine is an oral fluoropyrimidine that undergoes a three-step enzymatic conversion to 5-FU with the last step occurring in the tumor cell. For patients with metastatic colon cancer, two studies have demonstrated the equivalence of capecitabine to 5-FU-leucovorin.[22,23]

    For patients with stage III colon cancer, capecitabine provides equivalent outcome to intravenous 5-FU and leucovorin.

    Evidence (capecitabine):

    1. A multicenter European study compared capecitabine (1,250 mg/m2) administered twice daily for days 1 to 14, then given every 21 days for eight cycles against the Mayo Clinic schedule of 5-FU and low-dose leucovorin for patients with stage III colon cancer.[24]
      • The study demonstrated that DFS at 3 years is equivalent for patients receiving capecitabine or 5-FU-leucovorin (hazard ratio [HR], 0.87; P < .001).[24][Level of evidence: 1iiDii]
      • Hand-foot syndrome and hyperbilirubinemia were significantly more common for patients receiving capecitabine, but diarrhea, nausea or vomiting, stomatitis, alopecia, and neutropenia were significantly less common.
      • Of patients receiving capecitabine, 57% required a dose modification.
      • For patients with stage III colon cancer in whom treatment with 5-FU-leucovorin is planned, capecitabine is an equivalent alternative.


    Oxaliplatin has significant activity when combined with 5-FU-leucovorin in patients with metastatic colorectal cancer.

    Evidence (oxaliplatin):

    1. In the 2,246 patients with resected stage II or stage III colon cancer in the completed Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC [NCT00275210]) study, the toxic effects and efficacy of FOLFOX4 were compared with the same 5-FU-leucovorin regimen without oxaliplatin administered for 6 months.[25] Based on results from the MOSAIC trial, adjuvant FOLFOX4 demonstrated prolonged OS for patients with stage III colon cancer compared with patients receiving 5-FU-leucovorin without oxaliplatin.[26]
      • The preliminary results of the study with 37 months of follow-up demonstrated a significant improvement in DFS at 3 years (77.8% vs. 72.9%, P = .01) in favor of FOLFOX4. When initially reported, there was no difference in OS.[26][Level of evidence: 1iiDii]
      • Further follow-up at 6 years demonstrated that the OS for all patients (both stage II and stage III) entered into the study was not significantly different (OS = 78.5% vs. 76.0%; HR, 0.84; 95% confidence interval [CI], 0.71-1.00). On subset analysis, the 6-year OS in patients with stage III colon cancer was 72.9% in the patients receiving FOLFOX4 and 68.7% in the patients receiving 5-FU-leucovorin (HR, 0.80; 95% CI, 0.65-0.97, P = .023).[26][Level of evidence: 1iiA]
      • Patients treated with FOLFOX4 experienced more frequent toxic effects consisting mainly of neutropenia (41% >grade 3) and reversible peripheral sensorial neuropathy (12.4% >grade 3).
    1 | 2 | 3 | 4
    Next Article:

    Today on WebMD

    Colorectal cancer cells
    The right diagnosis is the most important factor.
    man with a doctor
    Our health check will steer you in the right direction.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    bladder cancer x-ray
    Do you know the warning signs?
    Colon vs Rectal Cancer
    New Colorectal Treatments
    can lack of sleep affect your immune system
    Cancer Facts Quiz
    Virtual Colonoscopy
    Picture of the Colon
    Vitamin D